MOLN Molecular Partners AG
Molecular Partners AG (MOLN) is expected to report earnings on August 26, 2026, after the market close. The consensus earnings estimate is a loss of $0.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on May 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot.
Sector
Healthcare
Industry
Biotechnology